Ocumension Therapeutics announced that OT-1001 (ZERVIATE), a potent and highly selective histamine-1 receptor antagonist with anti-allergic properties, has been included in the priority review and approval process of National Medical Products Administration of the People's Republic of China ("NNMPA") recently. OT-1001 (ZER VIATE) was developed by Nicox Ophthalmics Inc. ("Nicox"). The Group obtained an exclusive license from Nicox to develop, make, have made, import, export, use, distribute, market, promote, offer for sale and sell (or otherwise commercialize) OT-1001 (ZerVIATE) in the Greater China region in March 2019, and extended the exclusive rights to 11 countries in Southeast Asia in March 2020. OT-1001 is the first and only eye drop formulation of the antihistamine cetirizine, the active ingredient in ZYRTEC®?, and is currently commercialized in the United States for ocular itching associated with allergic conjunctivitis. In April 2023, the new drug application for OT-1001 (ZERVATE) was accepted by NMPA. The priority review and approval process of NMPA is designed to expedite the approval of drugs that address unmet medical needs or have the potential to offer significant improvements over existing treatment options. The inclusion of OT-1001 (ZERviATE) in the priority review and approval processes of NMPA will accelerate the review and approval process of its new drug application, which is an important step towards commercialization of OT-1001 (Zer VIATE). Cautionary Statement: The Company cannot guarantee that it will ultimately commercialize OT-
1001 (ZERVIATE) successfully. Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.